{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:15Z","timestamp":1793422635789,"version":"4.5.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,7,15]]},"DOI":"10.2169\/internalmedicine.9518-17","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T17:18:26Z","timestamp":1519751906000},"page":"2029-2034","source":"Crossref","is-referenced-by-count":37,"title":["Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody"],"prefix":"10.2169","volume":"57","author":[{"given":"Michiru","family":"Shiba","sequence":"first","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Inaba","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ariyasu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Kawai","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Inagaki","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Matsuno","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Iwakura","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nishi","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akamizu","sequence":"additional","affiliation":[{"name":"The First Department of Medicine, Wakayama Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Blank CU, Enk A. Therapeutic use of anti-CTLA-4 antibodies. Int Immunol 27: 3-10, 2015.","DOI":"10.1093\/intimm\/dxu076"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19: 813-824, 2007.","DOI":"10.1093\/intimm\/dxm057"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 19;363: 711-723, 2010.","DOI":"10.1056\/NEJMoa1003466"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 28;366: 2443-2454, 2012.","DOI":"10.1056\/NEJMoa1200690"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol 28: 278-287, 2016.","DOI":"10.1097\/CCO.0000000000000293"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98: 1361-1375, 2013.","DOI":"10.1210\/jc.2012-4075"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384, 2015.","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Win MA, Thein KZ, Qdaisat A, Yeung SJ. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med 35: 1039.e5-1039.e7, 2017.","DOI":"10.1016\/j.ajem.2017.02.048"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F. A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother 66: 25-32, 2017.","DOI":"10.1007\/s00262-016-1913-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gaudy C, Cl\u00e9vy C, Monestier S, et al. Anti-PD1 Pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 38: e182-e183, 2015.","DOI":"10.2337\/dc15-1331"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tel\u00f3 GH, Carvalhal GF, Cauduro CGS, Webber VS, Barrios CH, Fay AP. Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma. Ann Oncol 28: 191-192, 2017.","DOI":"10.1093\/annonc\/mdw447"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Trainer H, Hulse P, Higham CE, Trainer P, Lorigan P. Hyponatraemia secondary to nivolumab-induced primary adrenal failure. Endocrinol Diabetes Metab Case Rep [Internet]. 2016 Nov 1.","DOI":"10.1530\/EDM-16-0108"},{"key":"13","unstructured":"13. Shibasaki S, Imagawa A, Hanafusa T. Fulminant type 1 diabetes mellitus: a new class of type 1 diabetes. Adv Exp Med Biol 771: 20-23, 2012."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Nakamura K, Kawasaki E, Imagawa A, et al. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 34: 2084-2089, 2011.","DOI":"10.2337\/dc10-2274"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bowyer S, Prithviraj P, Lorigan P, et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 114: 1084-1089, 2016.","DOI":"10.1038\/bjc.2016.107"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'. Br J Cancer 116: e14, 2017.","DOI":"10.1038\/bjc.2017.58"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175, 2010.","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Vita R, Guarneri F, Agah R, Benvenga S. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination. Thyroid 24: 390-394, 2014.","DOI":"10.1089\/thy.2013.0170"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Zarour HM, Kirkwood JM, Kierstead LS, et al. Melan-A\/MART-1 (51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4 (+) T cells. Proc Natl Acad Sci U S A 97: 400-405, 2000.","DOI":"10.1073\/pnas.97.1.400"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mannering SI, Harrison LC, Williamson NA, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 202: 1191-1197, 2005.","DOI":"10.1084\/jem.20051251"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pociot F, Lernmark \u00c5. Genetic risk factors for type 1 diabetes. Lancet 387: 2331-2339, 2016.","DOI":"10.1016\/S0140-6736(16)30582-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 11: 533-542, 2011.","DOI":"10.1007\/s11892-011-0223-x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pizarro C, Garc\u00eda-D\u00edaz DF, Codner E, Salas-P\u00e9rez F, Carrasco E, P\u00e9rez-Bravo F. PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes Metab Res Rev 30: 761-766, 2014.","DOI":"10.1002\/dmrr.2552"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Fujisawa R, Haseda F, Tsutsumi C, et al. Low programmed cell death-1 (PD-1) expression in peripheral CD4 (+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 180: 452-457, 2015.","DOI":"10.1111\/cei.12603"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Imagawa A, Hanafusa T. Fulminant type 1 diabetes--an important subtype in East Asia. Diabetes Metab Res Rev 27: 959-964, 2011.","DOI":"10.1002\/dmrr.1236"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061, 2003.","DOI":"10.1126\/science.1079490"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Caturegli P, Di Dalmazi G, Lombardi M, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol 186: 3225-3235, 2016.","DOI":"10.1016\/j.ajpath.2016.08.020"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198: 63-69, 2003.","DOI":"10.1084\/jem.20022125"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kochupurakkal NM, Kruger AJ, Tripathi S, et al. Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS One 9: e89561, 2014.","DOI":"10.1371\/journal.pone.0089561"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Ohtsuki Y, Watanabe R, Kimura M, et al. Usefulness of KL-6 in the subtyping of intraductal papillary mucinous neoplasia of the pancreas, including carcinoma, dysplasia, and hyperplasia. Med Mol Morphol 48: 85-91, 2015.","DOI":"10.1007\/s00795-014-0080-1"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/14\/57_9518-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T20:03:15Z","timestamp":1570824195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/14\/57_9518-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,15]]},"references-count":30,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9518-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,15]]}}}